Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary

August 3, 2023

NASDAQ US Health Care Biotechnology earnings 63 min

Earnings Call Speaker Segments

Diane Weiser

executive
#1

Good afternoon, everyone, and thank you for being with us on today's call. Robert Blum, our President and Chief Executive Officer, is going to kick things off with a look at the quarter and what's happened recently. Fady Malik, who serves as EVP of R&D, will give updates on aficamten, with a focus on SEQUOIA-HCM, REDWOOD-HCM, and FOREST-HCM. Steve Heitner, our VP, Clinical Research and Therapeutic Area lead, Cardiovascular, is sitting in for Stuart Kupfer today, and he'll share further aficamten updates concerning MAPLE-HCM and talk about when ACACIA-HCM is expected to begin. Andrew Callos, EVP and Chief Commercial Officer, will discuss commercial readiness efforts for aficamten along with its market opportunity. Robert Wong, VP and Chief Accounting Officer, will walk through a financial overview of the quarter just completed; and Ching Jaw, SVP and Chief Financial Officer, will cover our financial outlook and the revised spending guidance for 2023. Last of all, Robert Blum will give an update on our early clinical programs during his closing remarks and go over anticipated upcoming milestones. Please be aware that parts of the discussion that follows, including how we answer questions, include statements tied to future events and performance instead of historical facts, and those constitute forward-looking statements. What actually happens could differ materially from what these forward-looking statements project. Details about factors that might lead our actual results to differ materially from those in these forward-looking statements can be found in our SEC filings, including our current report on our second quarter 2023 financial results filed on Form 8-K that was furnished to the SEC today; we take on no obligation to update any forward-looking statements after this call. And with that, I'll hand the call over to Robert.

Robert Blum

executive
#2

Thanks, Diane, and I’m glad all of you could join us for today’s call. We made substantial progress in the second quarter, advancing and broadening the aficamten development program while also achieving further momentum throughout our earlier-stage specialty cardiovascular pipeline. Fady and Steve will walk you through more specifics, but our extensive clinical trial work for aficamten is running at full capacity. During the quarter, we completed enrollment in SEQUOIA-HCM. We started MAPLE-HCM, and we got ready to launch ACACIA-HCM, the Phase III clinical trial of aficamten in patients who have nonobstructive HCM. That trial’s time line has been accelerated, and we now expect patient enrollment to start next month. It’s worth noting that soon aficamten will have 3 ongoing Phase III clinical trials, plus the open-label extension — a reflection of our corporate reprioritization and the exceptional work of our dedicated regulatory technical operations, clinical research, and operations teams, as well as the strong enthusiasm and diligence shown by our clinical site investigators and their staff; with enrollment in SEQUOIA-HCM now complete, study conduct is progressing, and we continue to expect to share top line results by the end of this year. Every patient in this trial has gone through the dose escalation phase, and we’re monitoring key metrics in blinded data, including patients randomized, baseline characteristics, standard deviation around endpoints, early terminations and missing data. I’m pleased to say that on each of these measures, SEQUOIA-HCM is performing well and is meeting or exceeding our trial design assumptions. Also, as we get ready for reporting on top line results, our regulatory supply chain and commercial readiness teams have been occupied with many activities, including go-to-market plans that build towards potential approvals and commercialization of aficamten. Andrew will share some of those plans shortly. While aficamten may be top of mind, our clinical research activities have at the same time continued advancing on other fronts. During the second quarter, we moved CK-586, a second cardiac myosin inhibitor, into a Phase I study; the Phase I study of CK-136, our cardiac troponin activator, is ongoing, and we carried on nonclinical research and IND-enabling activities toward our goal of submitting 1 to 2 new INDs over the next 1 to 2 years. Additionally, in response to corporate setbacks earlier in 2023. And as we signaled on our last earnings call, we have cut operating spending by approximately 15% relative to our initial 2023 financial guidance, with a sharper focus on our priorities and pipeline, including preparations for the potential approval and commercialization of aficamten. All of this will allow us to extend our cash runway even further. Ching will give more details and updated financial guidance for 2023 later in this call. The message we have for you this session is that we hold genuine momentum going into the second half of the year, supported by an extensive pipeline that covers early as well as late stages, ongoing research work, and a stronger financial footing — everything that fuels our conviction and confidence that we will meet our objectives for the rest of the year and find ourselves well placed past it. That said, I'll now turn it over to Fady. In 2020, those same priorities held.

Fady Malik

executive
#3

Appreciate that, Robert. During Q2, we achieved significant strides throughout the extensive development initiative for aficamten. The most notable development is that we finished enrolling and randomizing participants in SEQUOIA-HCM, our registrational Phase III study of aficamten, with 282 patients randomized — exceeding our target of 270 patients — which now makes it the biggest randomized clinical trial ever run for an investigational treatment in obstructive HCM patients. Running SEQUOIA-HCM is helped enormously by the experience and knowledge we've accumulated regarding cardiac myosin inhibitors, along with the assessment methods for their efficacy and the preferences of both patients and physicians. I'm happy to report that we likewise achieved or surpassed our goals for enrollment regarding both geographic distribution and patient traits. SEQUOIA-HCM drew a varied patient group spanning the U.S., China, Europe, and Israel. Those enrolled show a significant impairment in exercise capacity — a crucial component of the enrollment criteria, given that the primary endpoint evaluates a possible gain in exercise capacity. To build on that, SEQUOIA-HCM uses a strategy of individualized dose titration, intended to refine dose choice and boost the potential benefit-risk profile of aficamten; as a matter of fact, every patient has now gone past at least the 8-week visit, which represents the conclusion of the dose escalation stage; we keep gathering increasing amounts of blinded efficacy and safety information that we track carefully, covering items such as the standard deviation surrounding the primary endpoint, how completely endpoints are captured, the count of early terminations, and blinded safety information. Looking at all of these metrics, we believe SEQUOIA-HCM is advancing according to plan, definitely aligning with or beating our trial design assumptions. Our development operations and medical groups are diligently working to gather and clean the data as it builds up, along with the program analyses and tables required to report results swiftly once we lock the database when the trial concludes. All of this effort has positioned us to report top line results before the year ends. Since all SEQUOIA-HCM patients are now randomized, we anticipate also sharing baseline characteristics for these patients at the HCM Society Scientific Sessions in early October. Additionally, in the quarter, we shared fresh data on non-obstructive HCM patients from Cohort 4 of REDWOOD-HCM at the Heart Failure 2023 Congress, expanding on preliminary data shared earlier in the year at ACC. Those findings demonstrated that after just 10 weeks of treatment, aficamten was linked to an average gain of 11 points in the clinical summary score of the Kansas City Cardiomyopathy Questionnaire, or KCCQ CSS, with 58% of patients seeing a clinically meaningful decrease in symptom burden of 5 points or more. Aficamten treatment also came with better NYHA functional class, less angina frequency, and improved high-sensitivity cardiac troponin I and NT-proBNP; it's encouraging that the majority of patients reached the maximum dose available, 15 milligrams, with zero discontinuations caused by adverse events tied to aficamten, zero treatment interruptions or down titration events linked to LVEF below 50%, and zero events involving LVEF below 40%; our confidence in what aficamten can offer in nonobstructive HCM remains strong, and we're eager to launch a Phase III clinical trial in nonobstructive HCM before long. Steve is going to go into detail about that trial shortly. Before passing things to Steve, I'd also like to give an update on FOREST-HCM, the open-label extension study for patients finishing their participation in REDWOOD-HCM, SEQUOIA-HCM, and now MAPLE-HCM too. It's good to see that almost every patient chooses to keep going into the open-label extension, and we've got patients who have now gone beyond 2 years on aficamten and FOREST-HCM; beyond giving us efficacy data on long-term aficamten use for treating obstructive HCM, FOREST-HCM is also delivering safety and efficacy data in a manner that's highly relevant to real-world clinical practice, since investigators are empowered to adjust doses based on their own clinical judgment and can even stop other background medical therapy for HCM to make their patient's medical regimen simpler. We'll keep sharing data from FOREST-HCM periodically, and we expect it to play an important part in the next-in-class profile for aficamten and to illuminate its possible ease of use and safety, how durable its effects are, and its tolerability. With that, I'll hand the call to Steve, who is filling in for Stuart, who can't be with us on our earnings call today. Steve will discuss the growing development program for aficamten.

Steve Heitner

executive
#4

Appreciate that, Fady. Over the course of this quarter, we shared news that patient enrollment had begun in MAPLE-HCM, our Phase III study of aficamten used alone versus metoprolol used alone in people who have obstructive HCM; and it's a pleasure to tell you that the earliest participants were randomized just recently. Though it's not our expectation that MAPLE-HCM sits on the critical path toward a possible initial FDA approval, — should it succeed in showing aficamten's superiority over metoprolol when it comes to bettering exercise capacity, heart failure symptoms and New York Heart Association functional class, our expectation would be to file the findings from this study as a supplemental NDA aimed at a possible label expansion. There's potential for MAPLE-HCM to substantially broaden the way physicians anticipate employing aficamten, something that would probably show up in treatment guidelines, perhaps lifting it to first-line therapy and perhaps widening the commercial opportunity. Meanwhile, over recent months, we've kept up our preparations for the pivotal Phase III clinical trial of aficamten in nonobstructive HCM, drawing on the favorable data coming out of Cohort 4 of REDWOOD-HCM. As today's press release notes, we're naming this trial ACACIA-HCM, staying with our Northern California trees motif for the program. ACACIA-HCM means Assessment Comparing aficamten to Placebo on Cardiac endpoints In Adults with nonobstructive HCM; this pivotal clinical trial of aficamten in patients who have non-obstructive HCM should begin accepting patient enrollment next month, which is earlier than planned, highlighting how enthusiastic everyone is about this next trial. Beforehand, I want to share some key details about how it's designed. ACACIA-HCM is a Phase III multi-center randomized double-blind placebo-controlled clinical trial that should enroll roughly 420 patients who have symptomatic non-obstructive HCM. The primary endpoint is the change in KCCQ clinical summary school from baseline to week 36. Although the primary analysis happens at 36 weeks, patients will stay on treatment with aficamten or placebo for as long as 72 weeks so that additional secondary and exploratory analyses can be evaluated, including the time to the first cardiovascular event. As I said earlier, we anticipate starting patient dosing in ACACIA-HCM in September; with that, I'll hand the call to Andrew.

Andrew Callos

executive
#5

Appreciate that, Steve. When it comes to the possible approval and commercialization of aficamten in the United States as well as Europe, our commercial readiness team is putting all its energy behind the critical work streams. Over the quarter, we refreshed our go-to-market plans and keep sharpening them, carrying out the activities laid out in those plans — things like building a disease state education plan, branding, positioning, patient support programs, sales force deployment plans, and pricing assessments. We've additionally carried out further market research so we could see more clearly how ATM patients and HCPs experience things, and how HCPs, payers, and patients might react to the product profile we could potentially offer. A lot of these plans are going to be expanded once we have the results from SEQUOIA-HCM in hand, yet what our research has shown so far is encouraging when it comes to interest from payers, patients, and physicians, along with enthusiasm for a next-in-class cardiac myosin inhibitor. Our research keeps investigating what sets aficamten apart, such as its possible drug-to-drug interaction profile, and dose titration, both of which matter to patients and prescribers. It's our belief that a large unaddressed population of obstructive HCM patients exists and will continue to exist, and they could benefit from aficamten should it be approved. We're lucky that we could redeploy members of our commercial team who previously worked on omecamtiv mecarbil so they now work on aficamten — a corporate pivot that let us speed up our planning and operationalize efficiently our preparations for the potential approval and commercialization of aficamten. In the meantime, talks with payers moved forward in line with compliant payer interactions, with productive dialogue and education — not just regarding the HCM landscape and what cardiac myosin inhibitors might offer, but regarding aficamten in particular, in which they stay highly interested. We're eager to keep developing, expanding, and honing our go-to-market plans for the potential approval and commercialization of aficamten while at the same time delivering on the stepwise and systematic element of the pre-commercial runway. With that in mind, shifting to the market opportunity in Europe, we're happy to have brought on our first new hire in Europe, our Head of Europe, who has a proven track record in launching new products, delivering growth, and exceeding expectations in European and international markets within the rare disease and cardiology space; we look forward to having both our European Head of Access and medical affairs join us by the end of Q3; and we're pleased to be attracting top talent, thanks to our strong culture and pipeline. So with that, I'll hand the call over to Robert Wong.

Robert Wong

executive
#6

Thanks, Andrew. We closed out the second quarter holding $592.6 million across cash and investments. During Q2 2023, the revenue we recorded came from Astellas — it's the balance still owed to us under their $12 million commitment tied to how we ran COURAGE-ALS. R&D costs for the second quarter of 2023 rose to $83.2 million, up from $57.1 million in the same period of 2022, largely because of heavier spending on our cardiac myosin inhibition programs, which account for roughly 2/3 of what we put into R&D this quarter. G&A expenses for Q2 2023 landed at $39.7 million, a decline from $42.7 million in Q2 2022, mainly reflecting less outsourced work on commercial readiness efforts; and at this point Ching will walk through our financial outlook along with corporate development strategies.

Ching Jaw

executive
#7

Appreciate that, Robert. At the close of the quarter, we had roughly $593 million sitting on the balance sheet, and that equates to almost 2 years of cash runway, calculated off the revised 2023 spending guidance we announced today, which I'll now walk through in more detail. Before this, our projection for 2023 operating expenses had been somewhere between $420 million and $450 million, with net cash utilization of about $350 million to $375 million. We've now brought operating expenses down into the range of $390 million to $410 million, and that's a reaction to receiving a CRL from the FDA concerning the NDA for omecamtiv mecarbil, along with the discontinuation of COURAGE-ALS. Net cash utilization should now come in at approximately $310 million to $320 million; that decrease works out to savings of roughly 15%, showing the efforts we've undertaken to cut spending and hold back headcount growth given these setbacks. I'd also like to remind everyone that, consistent with the guidance we laid out previously and then revised, we anticipate collecting a $50 million nonrefundable milestone payment from Royalty Pharma when patient dosing begins in ACACIA-HCM, which should kick off next month. Beyond that, through this arrangement with Royalty Pharma, we still qualify for 2 further opportunities to bring in capital, should we decide to pursue them. $75 million if we potentially share positive results from the SEQUOIA-HCM, and $100 million if the NDA submission for aficamten in the U.S. gets accepted. We look at this transaction as being like a line of credit that we can draw on to bolster our balance sheet during 2024, if needed. With that goal in mind, we're currently in the middle of our annual strategic planning process, which takes a hard look at corporate and pipeline scenarios, contingencies and risk mitigations, and shapes investment decisions as we align with both the board and our shareholders; and with that, I'll hand the call back to Robert Blum.

Robert Blum

executive
#8

Thanks, Ching. As you've heard, we achieved a lot across the pipeline during Q2. Building on what my colleagues said, we also took part in a Type A meeting with the FDA this quarter to gain insight into the agency's perspective on the CRL for omecamtiv mecarbil. Beyond the U.S., that drug is currently under review in both Europe and China. Throughout the quarter, we kept supporting those reviews and responding to regulator questions. Our earlier-stage pipeline also moved forward. In Q2, we pushed CK-586 into a Phase I single ascending dose and multiple ascending dose trial, and the early progress so far has pleased us. CK-586 works as a cardiac myosin inhibitor, differs mechanistically from aficamten, and could potentially serve patients who have heart failure with preserved ejection fraction, or HFpEF, a condition with few available treatments. For certain HFpEF patients, the illness in many respects resembles nonobstructive HCM, given their thickened hearts, heightened cardiac contractility, and symptom burden. Promising results from cohort 4 of REDWOOD-HCM among non-obstructive HCM patients may serve as a proxy for how cardiac myosin inhibition could therapeutically apply to this population, which we hope to explore further with CK-586 in 2024. Simultaneously, our steady dedication to muscle biology research continues; alongside the ongoing early-stage programs for CK-136 and CK-586, we anticipate filing 1 to 2 more INDs for new drug candidates within the next 1 to 2 years. After those INDs are submitted, we will have moved forward 3 to 4 new drug candidates across a fairly brief period, a striking number for any biopharmaceutical company, allowing us to grow our pipeline in line with our Vision 2025 objectives. A tremendous amount of work is happening behind the scenes, and I have to thank our hardworking, devoted staff for their dedication to our future. On the finance and corporate development front, Ching already told you how we're doing right by shareholders by prioritizing company activities and related spending while also extending our cash runway. In addition, we keep advancing business development efforts focused on Japan and Europe as we look for possible partners for omecamtiv mecarbil and aficamten. Since we widened the aperture to partnering for aficamten in Europe during Q2, we have been actively engaging with prospective partners, and we're pleased with the progress and the level of interest we've gotten, along with the diligence and deal discussions concerning both aficamten and omecamtiv mecarbil. What came before is what makes our future possible. And this year, we've been marking our 25th anniversary, with an open house held recently at our headquarters in South San Francisco. We welcomed members of our nearby partner community, people who used to work here, backers, individuals receiving treatment, supporters, and local leaders, and it's been an honor that respected elected officials from the city and county nearby, plus staff who represent California state senators, came alongside us. It was a privilege to mark this happy event together with friends and backers of long standing, acknowledging in this moment that although a great deal remains unchanged from the time we launched Cytokinetics back in 1998, a great deal has shifted too, since we've moved closer to our bold objectives; and even so, the finest chapter lies ahead, should we succeed in delivering our first approved therapies for the good of patients. I'll now run through the milestones on the horizon. When it comes to aficamten, top line results from SEQUOIA-HCM ought to be shared before this year ends. We also anticipate that patient enrollment will keep going in MAPLE-HCM, with ACACIA-HCM set to begin in September 2023. In addition, throughout 2023 we'll keep pushing our go-to-market strategy forward. Regarding omecamtiv mecarbil, we anticipate carrying on with efforts to secure possible approvals internationally for this drug across Europe and China. As for CK-136, single ascending dose data from the Phase I study should arrive during the latter half of 2023; and lastly, for CK-586, enrollment in the Phase I study is expected to carry on across the whole year. With that, operator, let's please open the line now for questions.

Fatima Amanat

analyst
#9

Fatima here, calling in for Ash Verma at UBS. One quick question about CK-586. Its mechanism looks quite similar, though as you pointed out, it differs from aficamten. What makes you confident this mode of action will benefit HFpEF patients? Also, why not also go after obstructive HCM? And a fast second one: what efficacy benchmark would you use, and which clinical characteristics are you seeking in the Phase I trial?

Robert Blum

executive
#10

Sure. I'll hand things to Fady and Steve. First, though, let me note that CK-586 is deliberately being moved forward as something distinguishable from aficamten, which, as you know, is in development for obstructive disease and now nonobstructive HCM. If we had found any problems or liabilities with aficamten, then CK-586 might perhaps be developed in those same indications, but no such issues have come to our attention, which is why we believe 586 ought to stand on its own in a different disease state. So let me now pass it to Fady to address why we think this mechanism can translate to HFpEF, and what we might look for, both regarding Phase I data and eventually beyond that in HFpEF.

Fady Malik

executive
#11

Appreciate that, Robert. So as you were saying, CK-586 works through a mechanism that differs from aficamten, though both remain cardiac myosin inhibitors. What separates them comes down to a fairly subtle matter of the binding site and which state of the motor protein gets blocked. At the core, the effect is identical: fewer active cross bridges, lower cardiac contractility, plus a shallow exposure-response relationship just like aficamten has. That means its behavior is essentially quite similar. Robert already noted that aficamten is performing beautifully. Our view is that another HCM drug isn't truly needed, yet HFpEF represents a far different patient group, and an extremely large one too. With 586, our aim is to concentrate on that separate indication and on a subgroup of HFpEF patients whose phenotypes resemble certain of our HCM cases. Their hearts are bigger and thickened, filling pressures run high, biomarkers are elevated, they have symptoms, and their exercise tolerance is poor. In many respects, they are phenocopies of people carrying genetic nonobstructive HCM. So that's the path we'll take 586 down. As for Phase III, it's genuinely too early for me to say what we'll do, beyond concentrating, I believe, on that population mirroring nHCM most closely.

Robert Blum

executive
#12

I hope that's helpful. Operator, maybe now will move to the next question, please.

Rohit Bhasin

analyst
#13

Rohit here, filling in for Serge. Could you share what you anticipate regarding how quickly patients will enroll in both the MAPLE and ACACIA trials? Also, when are you intending to share any new data disclosures and medical meetings?

Robert Blum

executive
#14

Absolutely. Regarding MAPLE and ACACIA, which will be starting soon, I believe it's premature for us to provide guidance on enrollment pace. I get the question, and we owe you an answer on that. Still, let's observe how we move through this startup period and those first enrollments before we potentially begin giving guidance on enrollment rates and completion. Naturally, I don't anticipate any data coming out of either study in 2023; and turning to next year, I think that's likewise too early — we'll be better positioned to indicate what to expect for next year when we hold our Q4 earnings in February.

Jason Butler

analyst
#15

Congratulations on the advancement. In your prepared remarks, you mentioned that every patient in SEQUOIA has now completed the titration stage. I'm just curious whether you could share if what you're observing matches your expectations regarding the share of patients reaching target doses.

Robert Blum

executive
#16

Thanks for bringing that up, and as you point out, that's a significant milestone that we've now gotten past that dose escalation period. Bearing in mind that we're blinded to dose, but perhaps I'll turn it over to Steve if he'd like to add more.

Steve Heitner

executive
#17

Okay, Jason, I believe Robert already addressed that for you. Clearly, this trial is blinded, so we truly do not have visibility into the actual dose being given. That means the percentage of doses that patients in SEQUOIA are receiving is unknown to us; however, you've already been shown certain data from the FOREST-HCM study, which is not blinded, and in that case there is a pleasant bell-shaped curve for dosing, with patients mostly receiving 15 and 10 milligrams while a lesser share is receiving 5 and 20 milligrams.

Jason Zemansky

analyst
#18

Nice work on the advances. Let me return to a few things you said about MAPLE and the chance to expand aficamten's label so it covers first-line use. What opportunity do you see there, I wonder? Clearly the addressable market is large, yet it appears there might be logistical or administrative obstacles — think about payer pushback or possible capacity constraints among community prescribers. Do you view aficamten as a legitimate choice for every patient with obstructive HCM?

Robert Blum

executive
#19

Yes. Investigators themselves in FOREST, I believe, are showing us the way, since they opt to move patients off beta blockers, and they do so for reasons that carry real weight for physicians and patients. And in the end, should MAPLE succeed, I think payers will embrace it. Perhaps I'll turn to our clinical colleagues to see whether they wish to add something, and maybe Andrew too, if he'd like.

Fady Malik

executive
#20

Jason, it's Fady here. Let me just chime in that when you're talking about a medication targeting what's actually driving the illness, you clearly have a shot at changing how the disease itself progresses. So MAPLE isn't built — wasn't intended — to tackle that particular aspect. Still, when it comes to deciding which drug a patient should get, we at least offer proof about where the greatest efficacy might lie between whichever option currently ranks #1 that gets started and the newer entrant, the CMI. And as time goes on, our hope is to expand the rationale for bringing CMIs in sooner, given that they could potentially decelerate how the disease advances or hold its progression steady. So my sense is this marks the start of a plan to cement CMIs as first-line therapy.

Robert Blum

executive
#21

Andrew, is there anything you'd like to add?

Andrew Callos

executive
#22

Yes. Perhaps just one or two items, Jason. To start, when you have evidence, it definitely helps shape guidelines. Those guidelines will in turn definitely support the second point, from a payer perspective — perhaps removing the step that we currently have, or probably have, I should say, as a category involving beta blockers and/or calcium channel blockers. Based on what our research shows, that step appears to matter to physicians and to patients alike. If there's evidence that aficamten by itself can treat the disease effectively, then we believe that will definitely be a solid strategy on the commercial side too.

Joe Pantginis

analyst
#23

I appreciate the thorough update, and I'm excited about ACACIA getting underway. Robert, my question is going to ramble a bit, so please bear with me. Regarding the cost-savings efforts and related matters, do you feel the company is now appropriately sized? Or should we anticipate the possibility of further reductions in spending? Then, turning to aficamten, given that this trial spans many parts of the world, are there specific regions where you might place greater emphasis when it comes to how the clinical trial is run or how treatment protocols could differ from one area to another? And finally, on ACACIA, were there any outside factors that helped speed up when the study began?

Robert Blum

executive
#24

You're correct, that was quite a lengthy sentence, and I'm working to recall all the pieces. Let me begin with what I believe was the first component. I genuinely think — and Ching is welcome to weigh in on this as well if he'd like — that we carried out a very substantial effort to reduce costs, rigorously evaluating what we needed to accomplish in 2023 to better match a new set of circumstances, circumstances in which our attention is on aficamten, and where omecamtiv mecarbil, given the CRL, no longer figures into our near-term plans, while also acknowledging that reldesemtiv wasn't advancing in Phase III. We had to determine where we could shift personnel so they'd concentrate on that effort, which had become our fresh top priority, and that is aficamten, above all else. To accomplish this, we examined spending on outside vendors. We reviewed contractors and consultants, and we reviewed our own employee numbers. We likewise reviewed our intentions to add staff, and we established some demanding goals, and we hit those goals. I believe the team at Cytokinetics did an excellent job aligning everyone toward the same objective to make sure we could achieve a very meaningful decrease in operating expenses, not only across the longer horizon, but also in the shorter term, in order to lengthen our cash runway this year; and that is precisely what we accomplished by the time we held the Q1 earnings call. We understood our targets were ambitious, and we hadn't finished that process yet. That process was completed in Q2, and I think everyone cut back considerably. As a result, I believe we are appropriately sized for our present priorities and for where things stand today, acknowledging that aficamten will be forging the way forward for this organization, and we must be positioned as strongly as possible to take full advantage of that once we learn more from SEQUOIA, which will come at the close of this year; so let me first check whether Ching has anything to add.

Ching Jaw

executive
#25

Robert already addressed that thoroughly, I believe. One additional point from my side: within our strategic planning work, we're likewise evaluating various scenarios in case the SEQUOIA readout falls short of what we're hoping for — we've got scenario planning in place to handle that. Naturally, though, nothing can be acted on until the data arrives.

Robert Blum

executive
#26

Regarding what you were starting to say next, it may have had to do with differences across regions, and whether we were seeing anything or getting ready for anything. Perhaps I can hand it over to Fady or Steve to address that.

Steve Heitner

executive
#27

Alright, I'll handle that one — Steve here. Your question hinted at whether we're aiming at particular regions. My view is that Cytokinetics' approach has involved spreading a broad net and reaching every region. You're correct that there are differences in treatment or strategy regarding how patients get treated across various parts of the globe; even so, the design of SEQUOIA enrolls every patient with symptomatic obstructive HCM regardless of which medical therapy is accessible to them, disopyramide included or not. The one exception, I suppose, would be Japan, since cibenzoline therapy exists there, and as you're aware, we aren't conducting the trial in Japan. Yet regardless of whether septal reduction therapy is available — septal myectomy or alcohol septal ablation — you can see that we do include an endpoint measuring aficamten's effect on these patients' eligibility for it. And stepping back to examine the approach we've taken for HCM overall, we're — our development program targets not just every patient with obstructive HCM regardless of geography, but every patient with HCM regardless of phenotype, encompassing nonobstructive patients, those with midventricular obstruction that you've observed with our regulate in Cohort 4, plus ideally other subgroups down the road.

Robert Blum

executive
#28

Then there was a third component to what you were saying, and it's slipped my mind…

Diane Weiser

executive
#29

Is there any outside effect on ACACIA…

Fady Malik

executive
#30

On ACACIA or MAPLE, right. I'll handle that one. Regarding MAPLE, I'd say enthusiasm is substantial, considering the question we posed in that trial and the fact that this patient group differs somewhat from the other oHCM populations studied so far; and clearly, no large oHCM trials are currently underway; as for nHCM, our belief is that this marks the first instance a novel therapy has been tested in nHCM. Across the board, I'd expect investigator enthusiasm to run high.

Sean McCutcheon

analyst
#31

Sean here, filling in for Dane. Could you explain what strategic reasoning sits behind ACACIA having just one primary endpoint, KCCQ, when the parallel MAVA trial uses KCCQ plus pCO2 as co-primaries? Which physician input and FDA feedback shaped that choice? Also, is the decision to use a 36-week endpoint rather than a 48-week time point in Odyssey purely a function of how long titration is expected to take? If that's not the case, what else factored into it?

Robert Blum

executive
#32

Certainly. Steve, would you address those questions, please?

Steve Heitner

executive
#33

Okay, it's Steve here. As we said before, the main goal for SEQUOIA is a single measure — a shift in KCCQ — and that choice came from what we learned in our Phase II trial, REDWOOD Cohort 4, which was presented and whose data you've seen. We're also mindful that most people with non-obstructive HCM are on treatment with either a beta-blocker or a calcium channel blocker — in fact, usually a beta-blocker — and, as you're aware, that limits how much of a meaningful improvement in peak VO2 can be achieved. And our view was that if we combined these 2 endpoints into a composite as the primary endpoint, or dual primary endpoints, that would reduce the chances of success. Clearly, exercise capacity matters, and as Fady noted, we've built it in as a key secondary endpoint — exercise capacity measured through cardiopulmonary exercise testing. But basically, we believed that keeping those 2 separate would raise the odds of technical success for ACACIA-HCM. Was there a second part to your question?

Robert Blum

executive
#34

I'll address that. You brought up the comparison between 36 weeks and 48 weeks of treatment, and our selection landed on 36 weeks, which in my view provides ample time for reaching peak effects; the titration window in our trial is fairly brief, reflecting what we carried out in SEQUOIA; that's the choice we made; and as we noted afterward, following that primary endpoint patients continue to be tracked for a longer period, giving us the chance to observe whether additional efficacy builds up as time goes on.

Tessa Romero

analyst
#35

If I may, I'd like to pose something about HCM epidemiology at this point. In the past, you've referenced a U.S. patient population of 190,000 — those with a diagnosed obstructive form of HCM, plus, naturally, those who remain undiagnosed on top of that figure. From what I remember, Bristol cited 75,000 patients who were identified and diagnosed with obstructive disease, a number they quoted roughly when their launch occurred. Could you assist us in figuring out what that discrepancy amounts to? We'd genuinely appreciate gaining a clearer picture of your most current view regarding obstructive HCM epidemiology, particularly when considering diagnosed patients at the moment an AFE launch might happen? And how do you expect that to change over time?

Robert Blum

executive
#36

Absolutely. I'll hand things over to Andrew, who concentrates heavily on these topics as well as on how the literature continues to develop.

Andrew Callos

executive
#37

Absolutely, and I appreciate that question, Tess. Andrew here. There are several papers out there, a few of them older, that point to smaller figures for epidemiology. We conducted a 5-year longitudinal analysis using claims data involving patients who have an actual diagnosis. After that, we backed it up with more recent publications indicating roughly 190. Where BMS obtained their figure, I can't say. What I can say is that our confidence in that 190,000 figure is very high, and it's increasing somewhat faster than the population growth rate for oHCM. And once more, that's grounded in real claims data. So we're moving from that figure to 190, and beyond that, from our research, I believe it's important to recognize that roughly 60% of those individuals are not yet optimized on treatment and continue to experience symptoms, which is really what therapy is aimed at.

Yasmeen Rahimi

analyst
#38

Robert, to start, congrats on the milestone anniversary — a truly remarkable accomplishment for the whole organization. There are 2 things I'd like to ask Steve and Fady, and perhaps Andrew might weigh in as well. Something we keep hearing from many clients at this point is: from a safety standpoint, what do we need to see in the SEQUOIA trial that comes next that would justify differentiated echo monitoring? And what ramp would look favorable? I believe many clients grasp the lack of DDI, yet they might want to grasp how data from SEQUOIA might perhaps simply make us quite confident about a differentiated label; and I truly value your considered remarks on these matters, and I'll return to the queue.

Robert Blum

executive
#39

Certainly. I'll go to Fady first, though I want to emphasize, naturally, that what we will discuss reflects observations from REDWOOD and FOREST already, plus what we anticipate and hope to observe in SEQUOIA — but that remains unknown. Also, aficamten is still an investigational compound. So, with that said, I'll pass it to Fady to address your question.

Fady Malik

executive
#40

Okay. Yasmeen, when it comes to how echoes get tracked, what we expect is that the results from FOREST will support a monitoring schedule for echoes that patients and their physicians can realistically manage. I'm not going to give you head-to-head comparisons when you ask about what sets things apart. Even so, it's not hard to imagine that right now we're evaluating patients every 3 months; in the best case, those data would show no treatment decisions or safety events arising from any of those echos. The way I look at it, there's broad agreement that cardiograms create a burden on sites and on the healthcare system. There should be a widespread desire to lessen the burden on patients and on the healthcare system; so we're very pleased with how FOREST has played out. As I said earlier, we're currently following patients out to 2 years, and we hope this safety database will make a compelling argument for echo monitoring at, let's say, 2 times per year or possibly yearly in the future. Turning now to REMs, I think the key question is what kind of physician education will be needed before aficamten can be used; I can't address what you asked with that level of precision, other than to say it will be determined by the safety data and the remainder of aficamten's profile, and up to this point we don't think we have any meaningful drug-drug interactions or other drug characteristics that would call for extensive physician education; $190 million; so stay tuned. As more data come in, hopefully we'll have additional information to share.

Robert Blum

executive
#41

One thing that has given us a good deal of confidence in the clinical trial data we've reviewed so far is that we have not seen any early terminations tied to ejection fractions dropping unexpectedly among patients who have obstructive HCM. As the SEQUOIA results get unblinded, we're going to watch whether that pattern holds, though this is the sort of item that could in the end play a role in what would count as a risk that a possible REMs program might mitigate. And on that front, we remain quite hopeful.

Salim Syed

analyst
#42

So Robert, the number one thing people ask us — and I'm certain you hear it as well — is why has the stock dropped back to $30. A lot of folks are attempting to figure out precisely what's behind that level, and honestly, nobody expected it at any moment during 2023; and the explanations we're hearing from people, or what they seem to indicate, are the CAMZYOS-NRx line plus possible deal risk surrounding Afi; and I realize there's a one-question rule, so my attention is really on the deal risk part here. So since we're roughly 4 months from the SEQUOIA readout, I'm just wondering, in your conversations with possible partners, how is that specific element of the story being viewed, do people — do you believe folks will need to see that data? Or are you able to decide to go it alone or partner before that data? Just give us — if you could just provide some context for us regarding the timing of a possible deal, if there is one, or the go it alone or partner decision.

Robert Blum

executive
#43

Absolutely. So if we were to consider any transaction, it would have to meet what we're looking for — namely, the ability to enter Europe independently, while gaining something extra from a partner's involvement. That threshold is really very high. Doing a deal just to do a deal isn't what we're after, and should we enter into any transaction, it would support the corporate development work we're already carrying out, with the main focus being our own path into Europe. Andrew pointed out that our Head of Europe is already on board. We're adding additional personnel in that region as well. Our intention is to expand our commercial operations across Europe. During the previous quarterly call, I mentioned that we were broadening our view on possible partnerships for aficamten in Europe, though our main attention remained on Japan, and that we would pursue such a route only if we could demonstrate it would outperform doing everything ourselves. I won't reveal what we decided, but I can tell you that our European launch approach is still being carried out, and we are examining very carefully any options that could replace it. Objectively weighing that choice serves shareholder interests, in our view. That evaluation has been undertaken, it is ongoing, and our independent initiatives keep progressing nicely. I trust that addresses what you asked.

Salim Syed

analyst
#44

Yeah, I believe that proved useful.

Edwin Delfin

analyst
#45

Edwin here for Carter. We've got one question regarding what you expect to reveal in the SEQUOIA top line press release. How much does the myocardia level disclosure work as a solid reference point for what we should expect? Then, following up on that, with SEQUOIA realm approaching, what ought we to look for from you and/or how will you be showing up at the HFSA and AHA meetings this year?

Robert Blum

executive
#46

Well, we'll be present in full force at HFSA and AHA this year, plus the HCM Society Meeting in October, which lands in between them. I'd also add that since we've provided guidance pointing to results for SEQUOIA by the end of the year, you can reasonably anticipate the full on presentation of those results happening not at any of those meetings, but possibly at ACC, taking place in April 2024. And ACC maintains its own rules and limitations regarding what would be allowed for a presentation during their scientific sessions, and those differ from other meetings. If my memory serves, when Myocardia shared its data, it was just ahead of the ESC meeting that year. ESC operates under different restrictions than ACC does. So I'm not sure you can draw a comparison between what our disclosure will be in a top line release and what theirs was. That said, I will tell you we'll disclose whatever we judge to be material and informative to shareholders without putting a presentation at ACC at risk. And before we actually see the data, it's difficult to know precisely where that lands.

Justin Kim

analyst
#47

Perhaps as an add-on to that point. I'd like to pose something regarding what will be shown at AHA, and possibly what we should anticipate from FOREST. One would assume you have some knowledge gained from those who completed SEQUOIA. I'm curious whether we can look forward to learning how a number of those pivotal trial participants fared after coming off the drug and being retitrated, or titrated up from placebo, and then seeing that at AHA later in the year?

Robert Blum

executive
#48

Right. We aren't providing guidance toward any fresh FOREST data at AHA, but instead you heard us mention SEQUOIA baseline demographics at the HCM Society. When it comes to FOREST, giving updates at each medical meeting hasn't been our habit. That said, we do aim to deliver worthwhile updates whenever there's substantial new data available to share. And that will more probably happen when we get to ACC next year.

Srikripa Devarakonda

analyst
#49

To build on what Robert said before regarding the LV decline — I believe you'd noted previously that an unblinding event might occur if the LVEF drop turned out to be quite small. Could you clarify where that threshold sits — what counts as quite small? And if we haven't gotten word of it up to now, is it fair to conclude that it never took place?

Robert Blum

executive
#50

Fair question. I'll hand it over to Fady, and perhaps Steve, if he'd like to chime in.

Fady Malik

executive
#51

Okay, Kripa. Under the protocol, it seems quite straightforward — should a patient's ejection fraction drop under 40%, both the investigator and Cytokinetics ought to be notified. As of now, no events of that kind have come to our attention, which is fairly encouraging; any additional EF declines aren't something we have visibility into. Everything else stays blinded, and that won't change before the study wraps up.

Robert Blum

executive
#52

Appreciate it, operator, and thank you to everyone who took the time to be with us today. Clearly, there's a great deal happening at our company right now, since we're shifting our priorities, concentrating on aficamten, cutting back on expenses, and pushing our pipeline forward. And we believe we're handling this in a way that's very much in line with what shareholders ought to anticipate from us as we approach these significant milestones; we're eager to keep you informed about how we're progressing; we welcome any additional questions you may have and look forward to bringing you updates for the rest of this year. So with that, operator, let's wrap up this call.

Operator

operator
#53

Thanks for joining us, everyone. That brings today's conference call to a close. We appreciate your participation. You're free to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.